Table 1.

Univariate Analysis Relating Dichotomic Variables Included in the Study and Survival Free of Androgen-Independent Progression

	Log Rank	P Value
Age (≤ 70 years vs > 70 years)	3.27	.0723
Initial clinical stage (T1-2 vs T3-4)	0.01	.9095
Biopsy Gleason score (2–6 vs 7–10)	6.71	.0096
LHRH agonist (± bicalutamide)	0.99	.3188
Initial PSA (≤ 20 ng/mL or less vs > 20 ng/mL)	0.10	.7483
Testosterone breakthrough increases > 20 ng/dL	1.78	.1819
Testosterone breakthrough increases > 50 ng/dL	7.74	.0054

LHRH, luteinizing hormone-releasing hormone; PSA, prostate-specific antigen.

Reproduced with permission from Morote J et al.²¹